Nasarar Ilimi | Ƙungiyar Likitoci ta Lu Daopei ta Buga Wani Babban Bincike na Asibiti a cikin Mujallar Haematology ta Burtaniya
A wani gagarumin nasara ga Ƙungiyar Likitoci ta Lu Daopei, wani takarda mai taken binciken asibiti mai taken "Nazarin aminci da inganci na dashen ƙwayoyin halitta na allogeneic hematopoietic ga marasa lafiya da cutar sankarar lymphoblastic mai tsanani/lymphoma lymphoblastic waɗanda suka sami cikakkiyar sassauci bayan maganin T-cell na autologous CD7 chimeric antigen receptor" an buga shi a cikin sanannen sanannen Mujallar Nazarin Haematology ta Burtaniya (IF=5.1). Binciken, wanda Dr. Cao Xingyu ya rubuta tare da Farfesa Lu Peihua a matsayin marubucin da ya dace, ya mayar da hankali kan yuwuwar samun damar haɗa allo-HSCT ga marasa lafiya na R/R T-ALL da T-LBL waɗanda suka sami cikakkiyar sassauci (CR) bayan maganin CD7 CAR-T na autologous.
Bayanin Bincike:
Cututtukan ƙwayoyin T, kamar T-ALL da T-LBL, an san su da yanayinsu mai tsanani da kuma juriyar magani mai yawa. Ga marasa lafiya da ke fama da T-ALL/LBL mai tsauri ko kuma waɗanda suka sake kamuwa da cutar (R/R T-ALL/T-LBL), magungunan gargajiya suna ba da iyakataccen nasara da kuma mummunan hasashen da aka samu. Duk da haka, maganin CD7 CAR-T ya bayyana a matsayin wata babbar nasara, yana nuna babban alƙawarin magance waɗannan yanayi masu wahalar magani, duk da cewa har yanzu suna cikin matakan farko na gwaje-gwajen asibiti. Idan aka biyo baya tare da haɗa allo-HSCT, marasa lafiya da suka sami CR tare da maganin CD7 CAR-T ana ba su dama ta gaske don samun sauƙi na dogon lokaci.
Hanyar Nazarin:
Wannan binciken da aka yi a baya ya yi nazari kan marasa lafiya na R/R T-ALL da T-LBL waɗanda suka sami maganin NS7 CAR-T, sannan aka haɗa allo-HSCT tsakanin Nuwamba 2020 da Janairu 2023 a Asibitin Lu Daopei. Binciken ya binciki abubuwa daban-daban, ciki har da shekarun majiyyaci, lambar kwafin ƙwayoyin CAR-T kafin a dasa su, da kuma tsarin allurar CAR-T daban-daban, don tantance tasirinsu ga sakamakon dasa su. An kwatanta sakamakon da na marasa lafiya 124 waɗanda suka sami CR ta hanyar chemotherapy sannan aka biyo bayan allo-HSCT.
Muhimman Abubuwan da aka gano:
Binciken ya haɗa da marasa lafiya 34 na R/R T-ALL/T-LBL waɗanda suka sami CR bayan maganin NS7 CAR-T sannan daga baya aka yi musu allo-HSCT. Matsakaicin tazara tsakanin maganin CAR-T da dashen shine kwanaki 57.5. Abin lura shi ne, kashi 47.1% na marasa lafiya suna da cutar farko da ba ta da ƙarfi, yayin da kashi 52.9% suka sake kamuwa da cutar. Bayan jiko na CAR-T, cytokine release syndrome (CRS) ya faru a cikin marasa lafiya 33, tare da kashi 94.1% suna fuskantar CRS na aji 1-2. Abin farin ciki, babu wani mara lafiya da ya kamu da cutar neurotoxicity da ke da alaƙa da garkuwar jiki (ICANS).
A cikin kwanaki 28 bayan CAR-T, marasa lafiya 31 sun sami CR mai kama da MRD, yayin da marasa lafiya 3 suka sami CR mai kama da MRD. Binciken ya kuma gano cewa marasa lafiya da suka sami fashewar ƙashi ≤20% kafin a yi musu dashen sun sami raguwar komawar kashi 0% a watanni 18 bayan an yi musu dashen. Idan aka kwatanta da marasa lafiya da ke da CR mai kama da chemotherapy, jimillar rayuwa (OS) na shekaru 2 sun yi kama da juna: 61.9% ga ƙungiyar CD7 CAR-T idan aka kwatanta da 67.6% ga ƙungiyar chemotherapy. Bugu da ƙari, ƙimar rayuwa ta rashin cutar sankarar jini (LFS) na shekaru 2 kusan iri ɗaya ne (62.3% idan aka kwatanta da 62.0%).
Abin lura musamman, marasa lafiya 'yan shekara ≤14 da suka karɓi maganin CD7 CAR-T sun sami mafi kyawun kashi 87.5% na OS da LFS na shekaru 2. Sakamakon ya nuna cewa maganin CD7 CAR-T tare da allo-HSCT na iya bayar da madadin lafiya da inganci ga marasa lafiya na R/R T-ALL/T-LBL waɗanda ba su cancanci yin maganin gargajiya ba.
Kammalawa:
Binciken ya kammala da cewa haɗakar maganin CD7 CAR-T da allo-HSCT ya biyo baya yana ba da kyakkyawan tsarin magani mai inganci ga marasa lafiya na R/R T-ALL/T-LBL. Sakamakon ya yi daidai da waɗanda aka samu ta hanyar chemotherapy da allo-HSCT, ba tare da ƙaruwar mace-mace ba, wanda ke ba da zaɓi mai mahimmanci ga marasa lafiya da ke da ƙarancin zaɓuɓɓukan magani. Sakamakon binciken yana ba da bege na tsawon lokaci na gafara da rayuwa, musamman a cikin marasa lafiya masu haɗarin gaske waɗanda ke fuskantar haɗuwa da allo-HSCT akan lokaci.
Tasiri da Hasashen Nan Gaba:
Buga wannan bincike mai ban mamaki a cikin Mujallar Nazarin Haematology ta Burtaniyashaida ce ta sadaukarwa da ƙwarewar ƙungiyar likitocin Lu Daopei. Wannan nasarar ta nuna ƙoƙarin da asibitin ke yi na ci gaba da inganta maganin cututtukan jini da kuma gudummawar da suke bayarwa ga al'ummar likitocin duniya. Yana nuna yuwuwar maganin CD7 CAR-T a matsayin zaɓi mai kyau ga marasa lafiya da ke fama da R/R T-ALL/T-LBL kuma yana nuna jajircewar ƙungiyar wajen tura iyakokin ilimin jini. Maganin Ciwon daji.